Carcinogenesis Advance Access published online on September 7, 2007
Carcinogenesis, doi:10.1093/carcin/bgm199
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor binding protein-3 by inducing its ubiquitin/proteasome-dependent degradation
1 Cell Metabolism and Differentiation Research Group
2 Department for Molecular and Cellular Biology, Institute for Biomedical Aging Research of the Austrian Academy of Sciences, Rennweg 10, 6020 Innsbruck, Austria
3 Tumorvirology Group
4 Molecular Oncology Group, Tyrolean Cancer Research Institute, Medical University Innsbruck, Innrain 66, 6020 Innsbruck, Austria
* Corresponding author: Werner Zwerschke, Institute for Biomedical Aging Research and Tyrolean Cancer Research Institute, Rennweg 10, 6020 Innsbruck, Austria, Tel.: 0043-512-58391932, Fax: 0043-512-5839198, E-mail: werner.zwerschke{at}oeaw.ac.at
The E7 protein encoded by the oncogenic human papillomavirus type 16 has been shown to bind and inactivate insulin-like growth factor binding protein 3 (IGFBP-3), the pro-apoptotic product of a tumour suppressor gene; however, the molecular mechanism underlying E7 induced inactivation of IGFBP-3 remained uncertain. In this study, we map the IGFBP-3 binding domain for E7 to the nuclear localization signal in the conserved COOH-terminal domain of IGFBP-3. Moreover, we demonstrate that both proteins interact in the nucleus and that E7 induces polyubiquitination and proteasome-dependent proteolysis of nuclear IGFBP-3 in cervical cancer cells. This leads to a dramatic shortening of the half-life of nuclear IGFBP-3, whereas the stability of an E7-non-binding IGFBP-3 mutant is not affected by E7. Finally, we show that E7-mediated destruction of nuclear IGFBP-3 correlates with the inhibition of IGFBP-3-induced apoptotic cell death. These data are consistent with E7-induced ubiquitin/proteasome-dependent inactivation of nuclear IGFBP-3.
Received March 7, 2007; revised August 27, 2007; accepted August 28, 2007.